pharmaphorum

OCTOBER 23, 2020

Is a century-old vaccine a ‘game-changer’ for COVID-19? This year, as the COVID-19 pandemic has spread, there has been increased talk of statistics, modelling, predictive analytics, and using data to solve the serious issues we face. Understanding the link between COVID-19 and the BCG vaccine.

Vaccines 109

Vaccines Immunization Hospitals 109

pharmaphorum

OCTOBER 16, 2020

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. It started human testing of a protein subunit vaccine with partner GlaxoSmithKline last month. Russia approves second shot.

Vaccines 98

Vaccines 98

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines.

Vaccines 134

Vaccines Immunization Compounding Pharmaceutical Companies 134

pharmaphorum

NOVEMBER 12, 2020

In the hours after Pfizer’s momentous vaccine news emerged on Monday #pfizerproud popped up on my social media feeds again and again from the firm’s employees, both past and present. The phase 3 trial results are a huge advance in the fight against the global coronavirus pandemic. The scientists have done their job”.

Vaccines 86

Vaccines FDA 86

pharmaphorum

JULY 28, 2021

Continuing orders for Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty have prompted near one-third increase in its projected revenues for the vaccine this year, from $26 billion to $33.5 Comirnaty’s performance – $7.8 ” The sales forecast for 2021 is based on contracts to deliver 2.1

Vaccines 52

Vaccines 52

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on.

Vaccines 63

Vaccines Immunization 63

The Infectious Pharmacist

AUGUST 19, 2021

It does not merely refer to additional doses of a vaccine, but rather a booster dose refers to a dose with specific effects that is given after a “primary series” of a vaccine. Booster doses increase the quantity of antibodies produced by the body — and not just by a little. But wait, there’s more than just antibodies!

Immunization 52

Immunization Vaccines Hospitals FDA 52

pharmaphorum

SEPTEMBER 30, 2021

Pfizer’s new Prevnar 20 conjugate pneumococcal vaccine can be dosed at the same time as the seasonal flu jab, without any impact on either shot’s effectiveness, according to a new study. “However, vaccination rates decline when someone needs to make multiple appointments to receive these vaccines,” he added. .

Vaccines 52

Vaccines Immunization 52

pharmaphorum

AUGUST 25, 2021

Just a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has reported positive trial results in children that will ramp up the pressure on Pfizer and its market-leading Prevnar franchise.

Vaccines 105

Vaccines Labelling Immunization FDA 105

The Checkup by Singlecare

APRIL 3, 2024

The National Coffee Association reports that more Americans (up to 63%) drink coffee daily than any other beverage—including water. Prednisone is a corticosteroid —just like hydrocortisone and cortisone. “It If you start your day with a cup of coffee, you’re in good company.

Immunization 105

Immunization Specialty Pharmacies Dosage Labelling 105

pharmaphorum

JUNE 28, 2022

The question is, as one study was recently entitled , whether the current phase brings the world closer to the end of the pandemic or just to the end of the first phase? What is clear is that due to vaccines and therapeutics, the critical early phase of the pandemic is over. The current pandemic is still very much underway.

Vaccines 52

Vaccines 52

The Infectious Pharmacist

AUGUST 21, 2021

In this third post on booster doses I will go into more details about the upcoming booster doses and give my thoughts on what these booster doses mean going forward. Pfizer vs. Moderna and a note on vaccine dosing and timing. I remain skeptical that there is a meaningful difference between these two vaccines. In general, yes.

Vaccines 52

Vaccines Immunization Adverse Reactions Hospitals 52

pharmaphorum

DECEMBER 21, 2021

In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that took years (if not decades). This in turn provided them the focus they needed to conduct their sales outreach.

Pharmaceutical Companies 115

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 115

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Vaccines 111

Vaccines Immunization Hospitals 111

pharmaphorum

OCTOBER 28, 2020

Claus Møldrup explores research showing that patients want their voice to be heard more by pharma, and asks what a truly effective feedback loop for medicines might look like. That narrative, for many patients, is that pharma companies just don’t care”. Once a drug is licensed and launched, however, there is a deafening silence.

Vaccines 118

Vaccines Hospitals Pharmaceutical Companies Pharmaceutical Companies 118

pharmaphorum

SEPTEMBER 20, 2022

COVID-19 is still circulating and there are fears that further spikes in cases are to be expected in the coming months. Vaccines have transitioned from being a largely unloved area of the industry, with multiple big pharma companies divesting their vaccine divisions , to the biggest revenue drivers seen in recent years.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

JANUARY 15, 2021

While pharma has raced to develop COVID-19 vaccines, US-based company NeuroRx is taking a different approach to treating the virus. Every air-breathing warm-blooded animal makes this peptide to protect the lungs from the toxic effects of breathing air,” NeuroRx CEO, Jonathan Javitt, MD, MPH, told pharmaphorum. “It

Vaccines 145

Vaccines Hospitals FDA 145

European Pharmaceutical Review

FEBRUARY 14, 2023

Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. Progress on mRNA vaccines for RSV Moderna’s mRNA vaccine mRNA-1345 demonstrated vaccine efficacy of 83.7

Vaccines 97

Vaccines Immunization FDA 97

European Pharmaceutical Review

AUGUST 30, 2022

The COVID-19 pandemic has reminded the pharmaceutical industry of several key lessons. The successful roll-out of the global vaccination programme over the last 18 months was about more than just the ability of the industry to ramp up production to deliver billions of doses worldwide.

Vaccines 118

Vaccines Immunization 118

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works.

Vaccines 138

Vaccines Health and Personal Care Stores Immunization Packaging 138

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. The breakthrough was hailed as a revolution for disease treatment and particularly a major success against the pandemic. Where next?

Vaccines 110

Vaccines Immunization FDA 110

Hospital Pharmacy Europe

AUGUST 22, 2023

An interest in science during secondary school was the driver for Professor Ian Wong to study pharmacy. But he soon realised that in order to progress his career, he would need more training in this area, and a possible route to achieve this could be through undertaking a PhD in pharmacovigilance.

Vaccines 96

Vaccines Community Pharmacies Hospitals Communication 96

pharmaphorum

JULY 23, 2021

A real-world study carried out in Canada had found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce the chances of being hospitalised or dying from variants of concern dramatically, even after a single dose.

Vaccines 98

Vaccines Immunization Hospitals 98

pharmaphorum

DECEMBER 24, 2021

People infected with the Omicron variant of COVID-19 are 50% to 70% less likely to be admitted to hospital than those infected with other variants, according to a UK study. There was other more sobering news from the UKHSA study as well. Vaxzevria protects against the new variant.

Vaccines 52

Vaccines Hospitals 52

pharmaphorum

SEPTEMBER 3, 2021

Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to bring the first licensed shot to market. At its recent business update, GSK said it was anticipating peak sales of more than $4 billion for its vaccine if approved.

Vaccines 88

Vaccines Immunization 88

pharmaphorum

AUGUST 3, 2020

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The decision to advance LY-CoV555 into phase 3 comes just a couple of months after Lilly and AbCellera started testing the drug in clinical trials.

Nursing Homes 58

Nursing Homes Long-Term Care Facilities Immunization Vaccines 58

pharmaphorum

APRIL 7, 2022

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). billion if they reach the market, which would complement what many consider will be multibillion-dollar sales for the first effective RSV vaccine. .”

Vaccines 52

Vaccines Hospitals FDA 52

pharmaphorum

SEPTEMBER 1, 2021

Johnson & Johnson’s HIV vaccine candidate has failed its first major efficacy test, as it was unable to protect women against infection with the virus in a phase 2b trial carried out in sub-Saharan Africa. HIV was better at stimulating antibodies against HIV than an earlier version that targeted three antigens.

Vaccines 58

Vaccines Immunization 58

The Infectious Pharmacist

AUGUST 1, 2021

I feel a bit like Michael Corleone in Godfather Part 3 (yes, it’s the worst of the three, but it’s good for this line): Just when I thought I was out they pull me back in! Unfortunately the only messages about masks, vaccines, and COVID-19 that we’re hearing are: Just when you thought it was safe to go back in the water.

Vaccines 52

Vaccines Documentation Hospitals Communication 52